Suresh S. Ramalingam
Emory University · 1,248 works · 102,305 citations · h-index 125
Top works
- Comprehensive molecular profiling of lung adenocarcinoma
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- Genomic Classification of Cutaneous Melanoma
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- The repertoire of mutational signatures in human cancer
- Pan-cancer analysis of whole genomes
- Oncogenic Signaling Pathways in The Cancer Genome Atlas
- Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- Comprehensive Characterization of Cancer Driver Genes and Mutations
- Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc)
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component